Clinical Trial

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC

Study acronym: HEROS
Recruiting
View on ClinicalTrials.gov →
Summary
The HEROS study is an Italian observational multicenter prospective study aimed to investigate the current diagnostic and therapeutical approach towards HER2 mutated NSCLC in clinical practice. The enrolment will start in September 2024 until September 2025. A 12-months follow-up window will be performed.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-14.
Trial Details
NCT Number NCT07356544
Lead Sponsor Gruppo Oncologico Italiano di Ricerca Clinica
Collaborators: AstraZeneca
Conditions NSCLC (Advanced Non-small Cell Lung Cancer), HER2
Enrollment 50 participants
Start Date 2025-08-12
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05